A citation-based method for searching scientific literature

Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmidt. J Psychopharmacol 2016
Times Cited: 524







List of co-cited articles
910 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
628
86

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths. JAMA Psychiatry 2021
254
53

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
540
52

Trial of Psilocybin versus Escitalopram for Depression.
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt. N Engl J Med 2021
254
52

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
479
45

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
287
44

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
421
43


Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
362
37

Human hallucinogen research: guidelines for safety.
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
385
35

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
249
32

Psychedelics.
David E Nichols. Pharmacol Rev 2016
528
30

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Una McCann, Robert Jesse. Psychopharmacology (Berl) 2011
331
29

Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
304
29


Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
288
26

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Gabrielle I Agin-Liebes, Tara Malone, Matthew M Yalch, Sarah E Mennenga, K Linnae Ponté, Jeffrey Guss, Anthony P Bossis, Jim Grigsby, Stacy Fischer, Stephen Ross. J Psychopharmacol 2020
87
28

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
302
24

Long-term follow-up of psilocybin-facilitated smoking cessation.
Matthew W Johnson, Albert Garcia-Romeu, Roland R Griffiths. Am J Drug Alcohol Abuse 2017
186
23

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
278
23

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu, Roland R Griffiths, Matthew W Johnson. Curr Drug Abuse Rev 2014
192
23

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
517
22


The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects.
David B Yaden, Roland R Griffiths. ACS Pharmacol Transl Sci 2020
83
25

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
Robin L Carhart-Harris, David Erritzoe, Tim Williams, James M Stone, Laurence J Reed, Alessandro Colasanti, Robin J Tyacke, Robert Leech, Andrea L Malizia, Kevin Murphy,[...]. Proc Natl Acad Sci U S A 2012
423
20


Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Friederike Holze, Patrick Vizeli, Laura Ley, Felix Müller, Patrick Dolder, Melanie Stocker, Urs Duthaler, Nimmy Varghese, Anne Eckert, Stefan Borgwardt,[...]. Neuropsychopharmacology 2021
66
30

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer,[...]. Neuropsychopharmacology 2019
126
20


Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Frederick S Barrett, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2015
157
19

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell,[...]. EClinicalMedicine 2020
67
26

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Matthew W Johnson, Roland R Griffiths, Peter S Hendricks, Jack E Henningfield. Neuropharmacology 2018
111
18

Psychedelics and Psychedelic-Assisted Psychotherapy.
Collin M Reiff, Elon E Richman, Charles B Nemeroff, Linda L Carpenter, Alik S Widge, Carolyn I Rodriguez, Ned H Kalin, William M McDonald. Am J Psychiatry 2020
138
18


Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2016
148
17

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
141
17

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Rafael Faria Sanches, Flávia de Lima Osório, Rafael G Dos Santos, Ligia R H Macedo, João Paulo Maia-de-Oliveira, Lauro Wichert-Ana, Draulio Barros de Araujo, Jordi Riba, José Alexandre S Crippa, Jaime E C Hallak. J Clin Psychopharmacol 2016
215
16

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Erich Studerus, Michael Kometer, Felix Hasler, Franz X Vollenweider. J Psychopharmacol 2011
205
16

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy,[...]. Sci Rep 2017
197
16

Psychedelics and the essential importance of context.
Robin L Carhart-Harris, Leor Roseman, Eline Haijen, David Erritzoe, Rosalind Watts, Igor Branchi, Mendel Kaelen. J Psychopharmacol 2018
171
15

Predicting Responses to Psychedelics: A Prospective Study.
Eline C H M Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E Daws, Adam D G Hampshire, Romy Lorenz,[...]. Front Pharmacol 2018
107
15

Prediction of psilocybin response in healthy volunteers.
Erich Studerus, Alex Gamma, Michael Kometer, Franz X Vollenweider. PLoS One 2012
159
15

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H Preller, Franz X Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, Matthias E Liechti. Biol Psychiatry 2015
212
15

The pharmacology of psilocybin.
Torsten Passie, Juergen Seifert, Udo Schneider, Hinderk M Emrich. Addict Biol 2002
172
15

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.
Flávia de L Osório, Rafael F Sanches, Ligia R Macedo, Rafael G dos Santos, João P Maia-de-Oliveira, Lauro Wichert-Ana, Draulio B de Araujo, Jordi Riba, José A Crippa, Jaime E Hallak. Braz J Psychiatry 2015
230
14

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, Mendel Kaelen, Rosalind Watts, Robin Carhart-Harris. J Psychopharmacol 2019
74
18


Psychiatry & the psychedelic drugs. Past, present & future.
James J H Rucker, Jonathan Iliff, David J Nutt. Neuropharmacology 2018
104
14

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
176
14

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders.
Franz X Vollenweider, Katrin H Preller. Nat Rev Neurosci 2020
110
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.